$2.66
−18.31%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.12
From 52W high−98.03%
Volume89609.00
Market cap$4.77M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.12
From 52W high
−98.03%
Volume
89609.00
Market cap
$4.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
19.0
MomentumView details →
1D Return
−18.31%
YTD Return
−96.28%
SummaryUpdated Jun 1, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) is a clinical-stage biotechnology company that went public in November 2024. Founded as a biotech venture focused on developing innovative cancer treatments, the company specializes in advancing non-invasive therapeutic solutions for skin cancer. As a recently public entity, Medicus represents an early-stage biotech firm transitioning from private development to public markets while pursuing clinical trials for its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Medicus Pharma provided a shareholder update marking its third anniversary and outlining its progress and potential path to long-term value.12d agoMedicus Pharma submitted an optimized registrational protocol for Teverelix to the FDA for a partner-ready program in advanced prostate cancer.21d agoMedicus Pharma Ltd. announced an exclusive development focus for its SkinJect product in Gorlin syndrome following commercial, clinical and regulatory assessment.29d ago